US2022370422A1PendingUtilityA1
Compounds and compositions for treating hematological disorders
Est. expiryOct 31, 2037(~11.3 yrs left)· nominal 20-yr term from priority
Inventors:Robert Booher
A61K 31/635A61K 45/06A61K 2300/00A61K 31/437A61K 31/5377A61K 31/496A61P 35/02A61K 31/4545A61P 35/00A61P 7/06
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.
Claims
exact text as granted — not AI-modified1 - 116 . (canceled)
117 . A method of treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, comprising administering to the subject compound A and venetoclax, wherein
compound A is
and
the subject has a mutation in the TLR/IL-1R signaling pathway or the BCR signaling pathway.
118 . The method of claim 117 , wherein the subject has a mutation in the TLR/IL-1R signaling pathway.
119 . The method of claim 117 , wherein the subject has a mutation in the BCR signaling pathway.
120 . The method of claim 117 , wherein the subject has a mutation in both the TLR/IL-1R signaling pathway and the BCR signaling pathway.
121 . The method of claim 117 , wherein the subject has a mutation in MYD88.
122 . The method of claim 117 , wherein the subject has a L265P mutation in MYD88.
123 . The method of claim 117 , wherein the subject has a mutation in CD79B.
124 . The method of claim 117 , wherein the subject has a mutation in MYD88 and CD79B.
125 . The method of claim 117 , wherein the subject has a L265P mutation in MYD88 and a mutation in CD79B.
126 . The method of claim 117 , wherein the subject has a BCL translocation.
127 . The method of claim 117 , wherein the subject has a BCL translocation and a mutation in MYD88.
128 . The method of claim 117 , wherein the subject has a BCL translocation and a L265P mutation in MYD88.
129 . The method of claim 117 , wherein the subject has a BCL translocation and a mutation in CD79B.
130 . The method of claim 117 , wherein the subject has a BCL translocation; a mutation in MYD88; and a mutation in CD79B.
131 . The method of claim 117 , wherein the subject has a BCL translocation; a L265P mutation in MYD88; and a mutation in CD79B.
132 . The method of claim 117 , wherein the DLBCL is activated B-cell subtype DLBCL.
133 . The method of claim 118 , wherein the DLBCL is activated B-cell subtype DLBCL.
134 . The method of claim 119 , wherein the DLBCL is activated B-cell subtype DLBCL.
135 . The method of claim 120 , wherein the DLBCL is activated B-cell subtype DLBCL.
136 . The method of claim 121 , wherein the DLBCL is activated B-cell subtype DLBCL.
137 . The method of claim 122 , wherein the DLBCL is activated B-cell subtype DLBCL.
138 . The method of claim 123 , wherein the DLBCL is activated B-cell subtype DLBCL.
139 . The method of claim 124 , wherein the DLBCL is activated B-cell subtype DLBCL.
140 . The method of claim 125 , wherein the DLBCL is activated B-cell subtype DLBCL.
141 . The method of claim 126 , wherein the DLBCL is activated B-cell subtype DLBCL.
142 . The method of claim 127 , wherein the DLBCL is activated B-cell subtype DLBCL.
143 . The method of claim 128 , wherein the DLBCL is activated B-cell subtype DLBCL.
144 . The method of claim 129 , wherein the DLBCL is activated B-cell subtype DLBCL.
145 . The method of claim 130 , wherein the DLBCL is activated B-cell subtype DLBCL.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.